Corbus Pharmaceuticals (CRBP) Stock Forecast & Price Target

Compare

2,497 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRBP Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Corbus

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRBP Stock 12 Month Forecast

Average Price Target

$44.38

▲(358.47% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $44.38 with a high forecast of $53.00 and a low forecast of $28.00. The average price target represents a 358.47% change from the last price of $9.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","29":"$29","54":"$54","16.5":"$16.5","41.5":"$41.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,16.5,29,41.5,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.75,14,17.25,20.5,23.75,27,30.25,33.5,36.75,40,43.25,46.5,49.75,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.75,13.336923076923078,15.923846153846155,18.51076923076923,21.09769230769231,23.684615384615388,26.271538461538462,28.85846153846154,31.44538461538462,34.0323076923077,36.619230769230775,39.20615384615385,41.793076923076924,{"y":44.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.75,12.076923076923077,13.403846153846153,14.73076923076923,16.057692307692307,17.384615384615383,18.71153846153846,20.03846153846154,21.365384615384613,22.692307692307693,24.019230769230766,25.346153846153847,26.673076923076923,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$53.00

Average Price Target$44.38

Lowest Price Target$28.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$39

Buy

302.89%

Upside

Reiterated

12/12/25

In light of yday's stock weakness, we reiterate CRBP at Outperform.

Jeff Jones

Oppenheimer

$53

Buy

447.52%

Upside

Reiterated

12/12/25

Oppenheimer Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Oliver McCammon

LifeSci Capital

$53

Buy

447.52%

Upside

Reiterated

12/11/25

Optimistic Buy Rating for Corbus Pharmaceuticals: Promising Phase 1 Results for CRB-913 in Obesity TreatmentThis morning, Corbus (Nasdaq: CRBP) announced 1) an update from the Phase 1 SAD/MAD study tesng their CB1 receptor inverse agonist, called CRB-913, that is being developed for the treatment of obesity, and 2) iniaon of the placebo-controlled 12-week 1 trial tesng CRB-913 for n=240 obese, non-diabec paents. Stepping back for a moment, a key focus for investors (and ourselves) on Corbus' Phase 1 trial with CRB-913 is the safety and tolerability proﬁle of the asset, with parcular interest in the neuropsychiatric AEs given historical concerns. Speciﬁcally, the ﬁrst-generaon CB1R inverse agonist rimonabant was denied FDA approval due to suicidality concerns, while Novo Nordisk (NYSE: NVO) reported neuropsychiatric AEs with its second-generaon CB1R inverse agonist, monlunabant (our note on the monlunabant data HERE).

Andres Y. Maldonado

H.C. Wainwright

$40

Buy

313.22%

Upside

Reiterated

12/11/25

Buy Rating for Corbus Pharmaceuticals Driven by Promising CRB-913 Developments and Market PotentialValuation and Risks. Our 12-month price target of $40 is based on an equally weighted composite of (a) 39.24/ share, as a 15x multiple of taxed and diluted FY34 GAAP EPS of $2.62 discounted at 13%, and (b) an NPV of $39.91/ share (discount rate 13.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.

Andy Hsieh

William Blair

―

Buy

―

Reiterated

12/11/25

Promising Initial Results and Strong Safety Profile Bolster Buy Rating for Corbus Pharmaceuticals' CRB-913

Brian Abrahams

RBC Capital

$53

Buy

447.52%

Upside

Reiterated

12/11/25

RBC Capital says Corbus undervalued as '913 shows hints of weight lossRBC Capital says Corbus undervalued as '913 shows hints of weight loss

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$38

Buy

292.56%

Upside

Initiated

11/14/25

Wedbush Initiates a Buy Rating on Corbus Pharmaceuticals (CRBP)

Biren Amin

Piper Sandler

$35→$51

Buy

426.86%

Upside

Reiterated

10/20/25

Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Mayank Mamtani

B. Riley Securities

$28

Buy

189.26%

Upside

Reiterated

10/06/25

B. Riley Securities Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Kalpit Patel

Wolfe Research

$40→$28

Buy

189.26%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals price target lowered to $28 from $40 at B. RileyCorbus Pharmaceuticals price target lowered to $28 from $40 at B. Riley

Maury Raycroft

Jefferies

$70→$53

Buy

447.52%

Upside

Reiterated

03/11/25

Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Corbus Pharmaceuticals (CRBP)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$39

Buy

302.89%

Upside

Reiterated

12/12/25

In light of yday's stock weakness, we reiterate CRBP at Outperform.

Jeff Jones

Oppenheimer

$53

Buy

447.52%

Upside

Reiterated

12/12/25

Oppenheimer Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Oliver McCammon

LifeSci Capital

$53

Buy

447.52%

Upside

Reiterated

12/11/25

Andres Y. Maldonado

H.C. Wainwright

$40

Buy

313.22%

Upside

Reiterated

12/11/25

Andy Hsieh

William Blair

―

Buy

―

Reiterated

12/11/25

Promising Initial Results and Strong Safety Profile Bolster Buy Rating for Corbus Pharmaceuticals' CRB-913

Brian Abrahams

RBC Capital

$53

Buy

447.52%

Upside

Reiterated

12/11/25

RBC Capital says Corbus undervalued as '913 shows hints of weight lossRBC Capital says Corbus undervalued as '913 shows hints of weight loss

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$38

Buy

292.56%

Upside

Initiated

11/14/25

Wedbush Initiates a Buy Rating on Corbus Pharmaceuticals (CRBP)

Biren Amin

Piper Sandler

$35→$51

Buy

426.86%

Upside

Reiterated

10/20/25

Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Mayank Mamtani

B. Riley Securities

$28

Buy

189.26%

Upside

Reiterated

10/06/25

B. Riley Securities Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)

Kalpit Patel

Wolfe Research

$40→$28

Buy

189.26%

Upside

Reiterated

05/07/25

Corbus Pharmaceuticals price target lowered to $28 from $40 at B. RileyCorbus Pharmaceuticals price target lowered to $28 from $40 at B. Riley

Maury Raycroft

Jefferies

$70→$53

Buy

447.52%

Upside

Reiterated

03/11/25

Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Corbus Pharmaceuticals (CRBP)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corbus Pharmaceuticals

1 Month

xxx

Success Rate

5/10 ratings generated profit

Average Return

+10.05%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +10.05% per trade.

3 Months

xxx

Success Rate

5/10 ratings generated profit

Average Return

+1.11%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.11% per trade.

1 Year

Andres Y. MaldonadoH.C. Wainwright

Success Rate

5/12 ratings generated profit

Average Return

-11.60%

reiterated a buy rating 2 days ago

Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -11.60% per trade.

2 Years

xxx

Success Rate

5/12 ratings generated profit

Average Return

-11.88%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.67% of your transactions generating a profit, with an average return of -11.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRBP Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRBP has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRBP average Analyst price target in the past 3 months is 44.38.

Each month's total comprises the sum of three months' worth of ratings.

CRBP Financial Forecast

CRBP Earnings Forecast

Next quarter’s earnings estimate for CRBP is -$1.54 with a range of -$3.57 to -$0.94. The previous quarter’s EPS was -$1.90. CRBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CRBP has Performed in-line its overall industry.

CRBP Sales Forecast

Next quarter’s sales forecast for CRBP is $1.67M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $0.00. CRBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CRBP has Performed in-line its overall industry.

CRBP Stock Forecast FAQ

What is CRBP’s average 12-month price target, according to analysts?

Based on analyst ratings, Corbus Pharmaceuticals’s 12-month average price target is 44.38.

What is CRBP’s upside potential, based on the analysts’ average price target?

Corbus Pharmaceuticals has 358.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRBP a Buy, Sell or Hold?

Corbus Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Corbus Pharmaceuticals’s price target?

The average price target for Corbus Pharmaceuticals is 44.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $53.00 ,the lowest forecast is $28.00. The average price target represents 358.47% Increase from the current price of $9.68.

What do analysts say about Corbus Pharmaceuticals?

Corbus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of CRBP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Corbus Pharmaceuticals (CRBP) Stock Forecast & Price Target

CRBP Analyst Ratings

CRBP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Corbus Pharmaceuticals

CRBP Analyst Recommendation Trends

CRBP Financial Forecast

CRBP Earnings Forecast

CRBP Sales Forecast

CRBP Stock Forecast FAQ

Detailed List of Analyst Forecasts